Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Glenmark Pharmaceuticals Ltd. Share Price
Day's Range
Day's Range
Low
₹2,303.00
High
₹2,348.60
Price Summary
| Previous Close | ₹2,317.90 |
|---|---|
| Day's Range | ₹2,303.00 - ₹2,348.60 |
| Open | ₹2,334.60 |
| 52 Week Range | ₹1,792.60 - ₹2,474.00 |
| Volume | 2,37,421 |
| Market Cap | ₹0.07 |
| Previous Close | ₹2,306.00 |
|---|---|
| Day's Range | ₹2,304.85 - ₹2,346.60 |
| Open | ₹2,339.95 |
| 52 Week Range | ₹1,794.00 - ₹2,471.05 |
| Volume | 6,291 |
| Market Cap | ₹0.07 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 5,498.13 |
|---|---|
| Market Cap (₹ in Mn) | 0.07 |
| Dividend Yield(%) | 0.11 |
| Price/Earning (TTM) | 36.20 |
| TTM EPS (₹) | 63.70 |
| P/E Ratio | 44.21 |
| Book Value(₹) | 5.94 |
| PAT Margin (%) | 3.93 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 20.35 |
| Trade Value ( ₹ in Lacs) | 145.93 |
|---|---|
| Market Cap (₹ in Mn) | 0.07 |
| Dividend Yield(%) | 0.11 |
| Price/Earning (TTM) | 36.20 |
| TTM EPS (₹) | 63.70 |
| P/E Ratio | 44.21 |
| Book Value(₹) | 5.94 |
| PAT Margin (%) | 3.93 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 20.35 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 32644.4 | 92264.09 |
| Expenses | N/A | N/A |
| PBT | 955.78 | 21540.18 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 469.73 | 16103.5 |
About Glenmark Pharmaceuticals Ltd.
| Founded | 1977 |
|---|---|
| Managing Director | Glenn Saldanha |
| NSE Symbol | GLENMARK |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,56,089.58 | 1,900.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,26,975.64 | 8,550.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,85,638.53 | 4,880.50 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,24,503.13 | 8,659.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,216.02 | 1,426.20 | 1,165.70 - 1,165.70 |
| Lenskart Solutions Ltd. | 1,15,063.80 | 661.55 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,11,720.43 | 1,120.00 | 835.50 - 835.50 |
| Lupin Ltd. | 1,00,271.61 | 2,193.00 | 1,875.00 - 1,875.00 |
| Dr. Reddy's Laboratories Ltd. | 98,074.41 | 1,175.00 | 1,101.00 - 1,101.00 |
| Laurus Labs Ltd. | 98,047.76 | 1,814.65 | 823.10 - 823.10 |
No Records Found
Latest News
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch1 of Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) SingleDose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. Glenmark’s Calcium Gluconate Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Calcium Gluconate Injection, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) and 10,000 mg/100 mL (100 mg/mL), of Fresenius Kabi USA, LLC [NDA 208418].
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about media release
Glenmark Pharmaceuticals has informed that, Glenmark Pharmaceuticals (Glenmark) today announced the receipt of U.S. FDA approval1 for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray. Glenmark’s Fluticasone Propionate Nasal Spray USP is bioequivalent and therapeutically equivalent to the reference listed drug, Flonase®2 Nasal Spray, 0.05 mg/spray of Haleon US Holdings LLC [NDA 020121] and will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about allotment of shares under ESOP
Glenmark Pharmaceuticals has informed that the Company has allotted 23,863 Equity Shares of Re 1 each on August 10, 2026, to the grantee who had exercised the options under the Company's Employee Stock Option Plan 2016 (ESOP 2016). With this allotment, the paid-up capital of the Company has increased from Rs 28,22,00,809 divided into 28,22,00,809 number of equity shares of face value Re 1 each to Rs. 28,22,24,672 divided into 28,22,24,672 number of equity shares of face value Re 1 each. The details as required under the SEBI (Share Based Employee Benefits and Sweat equity) Regulations, 2021 are enclosed as Annexure - I.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
Glenmark Pharmaceuticals has informed that, Glenmark Specialty S.A. (Glenmark) today announced that U.S. FDA has approved the expanded use of RYALTRIS® (olopatadine hydrochloride and mometasone furoate) Nasal Spray, 665 mcg/25 mcg per spray, for the treatment of symptoms of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. With this approval, RYALTRIS® is now approved in the United States for adults and pediatric patients aged 6 years and older, extending this treatment option to a younger pediatric population. The company has attached media release.
The above information is a part of company’s filings submitted to BSE.
Glenmark Pharmaceuticals informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Glenmark Pharmaceuticals Ltd. is ₹2,317.90 as of 2026-08-21.
The market capitalisation of Glenmark Pharmaceuticals Ltd. is ₹65,081.01 as of 2026-08-21.
The 1-year return of Glenmark Pharmaceuticals Ltd. is 380.60% as of 2026-08-21.
The P/E ratio of Glenmark Pharmaceuticals Ltd. is 44.21 as of 2026-08-23.
The 52-week high and low of Glenmark Pharmaceuticals Ltd. are ₹2,474.00 and ₹1,792.60, respectively, as of 2026-08-21.
People Also Ask
Glenmark offers branded generics and specialty products in dermatology, respiratory, oncology, and cardiometabolic diseases across India, emerging markets, and regulated geographies.
Glenmark partners with others via out‑licensing, co‑development, contract manufacturing, and supplies high‑volume hospital‑based therapies and complex generics globally.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
